TY - JOUR
T1 - Angiopoietin-1 and Angiopoietin-2 Inhibitors
T2 - Clinical Development
AU - Gillen, Jessica
AU - Richardson, Debra
AU - Moore, Kathleen
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Purpose of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition. Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. Summary: The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.
AB - Purpose of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition. Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. Summary: The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.
KW - Angiogenesis
KW - Angiopoietin inhibition
KW - Anti-angiogenic therapy
KW - Tie2 inhibition
UR - http://www.scopus.com/inward/record.url?scp=85062145462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062145462&partnerID=8YFLogxK
U2 - 10.1007/s11912-019-0771-9
DO - 10.1007/s11912-019-0771-9
M3 - Review article
C2 - 30806847
AN - SCOPUS:85062145462
SN - 1523-3790
VL - 21
JO - Current oncology reports
JF - Current oncology reports
IS - 3
M1 - 22
ER -